{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Quijano Carde NA"],"funding":["NIDA NIH HHS","NIAAA NIH HHS","National Institutes of Health","NIAAA","NIDA","NIGMS NIH HHS","NIGMS"],"pagination":["108783"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8572579"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["199"],"pubmed_abstract":["Alcohol use disorder (AUD) is a neuropsychiatric condition affecting millions of people worldwide. Topiramate (TPM) is an antiepileptic drug that has been shown to reduce ethanol drinking in humans. However, TPM is associated with a variety of adverse effects due to its interaction with many receptor systems and intracellular pathways. GluK1-containing kainate receptors (GluK1*KARs) are non-selectively inhibited by TPM, and genetic association studies suggest that this receptor system could be targeted to reduce drinking in AUD patients. We examined the efficacy of LY466195, a selective inhibitor of GluK1*KAR, in reducing ethanol consumption in the intermittent two-bottle choice paradigm in mice. The effect of LY466195 on various ethanol-related phenotypes was investigated by quantificatio"],"journal":["Neuropharmacology"],"pubmed_title":["Antagonism of GluK1-containing kainate receptors reduces ethanol consumption by modulating ethanol reward and withdrawal."],"pmcid":["PMC8572579"],"funding_grant_id":["T32 GM008076","DA 036572","R01 AA023192","U01 AA025931","T32GM008076","K12 GM081259","K12GM081259","R01 DA036572"],"pubmed_authors":["De Biasi M","Feinn R","Quijano Carde NA","Kranzler HR","Perez EE"],"additional_accession":[]},"is_claimable":false,"name":"Antagonism of GluK1-containing kainate receptors reduces ethanol consumption by modulating ethanol reward and withdrawal.","description":"Alcohol use disorder (AUD) is a neuropsychiatric condition affecting millions of people worldwide. Topiramate (TPM) is an antiepileptic drug that has been shown to reduce ethanol drinking in humans. However, TPM is associated with a variety of adverse effects due to its interaction with many receptor systems and intracellular pathways. GluK1-containing kainate receptors (GluK1*KARs) are non-selectively inhibited by TPM, and genetic association studies suggest that this receptor system could be targeted to reduce drinking in AUD patients. We examined the efficacy of LY466195, a selective inhibitor of GluK1*KAR, in reducing ethanol consumption in the intermittent two-bottle choice paradigm in mice. The effect of LY466195 on various ethanol-related phenotypes was investigated by quantificatio","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-05-31T16:00:16.925Z","creation":"2025-04-04T12:46:10.176Z"},"accession":"S-EPMC8572579","cross_references":{"pubmed":["34509497"],"doi":["10.1016/j.neuropharm.2021.108783"]}}